We then evaluated the levels of tumor proteins from each group by immunohistochemical analysis, finding decreased levels of TAZ, C-MYC, RUNX2, N-cadherin, and CYR61 in ML323-treated tumors relative to those in controls (Fig. 5C), with these results confirmed by western blot analysis as well (Fig. 5D). This evidence concerns the gene MYC and neoplasm.